![Leigh Farrell](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Leigh Farrell
No más puestos en curso
Historial de carrera de Leigh Farrell
Antiguos cargos conocidos de Leigh Farrell.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Aviragen Therapeutics, Inc.
![]() Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Corporate Officer/Principal | - | - |
Johnson & Johnson Research Pty Ltd. | Director Técnico/Científico/I+D | 15/02/2011 | - |
Corporate Officer/Principal | - | 15/02/2011 | |
Gene Shears Pty Ltd. | Presidente | - | - |
BIOTA HOLDINGS LTD. | Corporate Officer/Principal | 28/07/2009 | - |
Estadísticas
Internacional
Australia | 4 |
Estados Unidos | 2 |
Operativa
Corporate Officer/Principal | 3 |
Chief Tech/Sci/R&D Officer | 1 |
President | 1 |
Sectorial
Health Technology | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 4 |
---|---|
Biota Holdings Pty Ltd.
![]() Biota Holdings Pty Ltd. Pharmaceuticals: MajorHealth Technology Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia. | Health Technology |
Johnson & Johnson Research Pty Ltd. | |
Gene Shears Pty Ltd. | |
Aviragen Therapeutics, Inc.
![]() Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
- Bolsa de valores
- Insiders
- Leigh Farrell
- Experiencia